Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Post by JayjayUSA12007on Jun 01, 2018 1:33am
317 Views
Post# 28109531

Why paying off EMD Sorono ?

Why paying off EMD Sorono ?
Link: https://finance.yahoo.com/news/theratechnologies-emd-serono-agree-early-202206426.html

Contractual obligations remaining with EMD Serono totalled US$28.2 million.
Thera paid off with a renegotiated price totalled UDS$23.85 million
The saving is: US$28.2 million - UDS$23.85 million = USD$4,350,000
So, the yearly saving would be USD$1,087,500/yr
The real interest expense for the payoff would be 5.75% of USD$23.85 million, not the entire USD$50 million, since the balance after paying off Serono would be used for other things.
Actual interest expense is: $23.85 million x 5.75% = USD$1.371 million/yr

So, the actual cost to payoff early is: USD$1.371 million - USD$1.087 = $284,000 / yr

The increase in Egrifta sales would more than offset this cost.
Bullboard Posts